Subcutaneous alemtuzumab for multiple sclerosis

Expert Review of Clinical Immunology

Volumn 8, Issue 5, 2012, Pages 423-426

  Tur, Carmen ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

alemtuzumab; intravenous route; monoclonal antibodies; multiple sclerosis; subcutaneous route

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; DACLIZUMAB; OFATUMUMAB; PLACEBO;

FATIGUE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LEUKEMIA; LYMPHOCYTE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; RASH;

EID: 84864984477     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.30     Document Type: Note

References (18)

1. Perumal JS, Foo F, Cook P, Khan O. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Mult. Scler. doi:10.1177/1352458511435716 (2012) (Epub ahead of print
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33(11), 1444-1452 (1983
3. Compston AC. McAlpine's Multiple Sclerosis. Churchill Livingstone Elsevier, PA, USA (2006
4. Kappos L, Radue EW, O'Connor P et al. FREEDOMS Study Group. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387-401 (2010
5. Polman CH, O'Connor PW, Havrdova E et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899-910 (2006
6. Horga A, Castillo J, Rio J et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev. Neurol. 52(6), 321-330 (2011
7. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975
8. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin. Immunol. 142(1), 25-30 (2012
9. Coles AJ, Compston DA, Selmaj KW et al. CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786-1801 (2008
10. Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46(3), 296-304 (1999
11. Hirst CL, Pace A, Pickersgill TP et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J. Neurol. 255(2), 231-238 (2008
12. Dearden CE, Khot A, Else M et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: Comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 118(22), 5799-5802 (2011
13. Bezares RF, Stemelin G, Diaz A et al. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/ refractory chronic lymphocytic leukemia: Final analysis. Leuk. Lymphoma 52(10), 1936-1941 (2011
14. Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsingremitting multiple sclerosis. Clin. Immunol. 142(1), 9-14 (2012
15. Wynn D, Kaufman M, Montalban X et al. CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A Phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 9(4), 381-390 (2010
16. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 142(1), 31-37 (2012
17. Soelberg Sorensen P, Drulovic J, Havrdova E, Lisby S, Graff O, Shackelford S. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS)- 24-week results of a Phase II study. Presented at: ECTRIMS. Gothenburg, Sweden, 13-16 October 2010.
18. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119(7), 2052-2061 (2009